Evidence map›Paper›PMID 32353946›Full record

ArticlePharmaceuticals (Basel, Switzerland)2020

Experimental Evaluation of Anticancer Efficiency and Acute Toxicity of Anthrafuran for Oral Administration.

Andrey E Shchekotikhin, Helen M Treshalina, Michael I Treshchalin, Eleonora R Pereverzeva, Helen B Isakova, Alexander S Tikhomirov

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Subchronic Toxicity Study of Oral Anthrafuran on Rabbits.Pharmaceuticals (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrey E ShchekotikhinGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.ORCID 0000-0002-6595-0811
Helen M TreshalinaFederal State Budgetary Institution «National Medical Research Center of Oncology of N.N.Blokhin», Ministry of Health of Russia, 24 Kashirskoye sh., Moscow 115548, Russia.
Michael I TreshchalinGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Eleonora R PereverzevaGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Helen B IsakovaGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.
Alexander S TikhomirovGause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow 119021, Russia.

Funding

Российский Фонд Фундаментальных Исследований (РФФИ) 20-33-70209
6 · The paper itself

Abstract

The new antitumor agent anthrafuran has demonstrated a consistent effect in murine tumor models when administered parenterally due to the simultaneous inhibition of multiple cellular targets such as topoisomerases I/II and protein kinases. In this study, we assessed the anticancer efficiency and acute toxicity of anthrafuran administered orally. The action of anthrafuran was studied on transplanted tumor models which included P388 leukemia, Ca755 mammary adenocarcinoma, LLC lung carcinoma, and T47D human breast cancer xenografts on Balb/c nude mice. A significant antitumor efficacy of oral anthrafuran was revealed for all tested tumor models as follows: T/C

Indexed as

acute toxicityanthrafuranantitumor activityLD50oral administration

Identifiers

PMID32353946
PMCPMC7281648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.